Phase 4 N=292 Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home
Influenza
Primary: Number of Participants Who Received Influenza Vaccine. — 250 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=903 Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil
Dose Schedule Study
Primary: Comparison of Antibody Response to HPV Type 16 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule. — 0.93; 0.99; 0.63; 1.0 GMT ratio
N/A N=3,076 SDH of HPV Vaccine Completion
Human Papilloma Virus
Primary: Overall HPV Vaccine Completion Rates — 1961; 1083 Participants
N/A N=1,235 Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination
Health Care Utilization · Vaccine Preventable Disease
Primary: Number of Participants Who Completed an Adolescent Well-care Visit — 43; 56; 55 Participants — p=0.165
N/A N=1,312 Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of MMR Vaccination
Preventable Disease, Vaccine · Health Care Utilization
Primary: Receipt of MMR Vaccination — 92; 77; 99; 104 Participants — p=0.531
N/A N=546 A Randomized Trial of Vaccine Adherence in Young Injection Drug Users
Medication Adherence · Substance Abuse, Intravenous · Risk Behavior
Primary: Vaccine Series Completion — 16; 20; 8; 10 participants
N/A N=2,868 Increasing Vaccine Uptake Among Adolescents in the Rural South
Vaccine Hesitancy
Primary: Difference in the Percentage of Adolescents Who Ever Received at Least One Dose of HPV Vaccination in the Intervention Group After the Intervention Implementation…
Phase 3 N=385 Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)
Neisseria Meningitidis · Bacterial Infections · Virus Diseases
Primary: Percentage of Participants With an Anti-Hepatitis B Surface Antigen (HBsAg) Antibody Titer ≥10 mIU/mL — 98.9 Percentage of Participants
Phase 4 N=456 Evaluation of the Human Rotavirus Vaccine at Varying Schedules and Doses in Rural Ghana
Rotavirus Gastroenteritis
Primary: Immunoglobulin A (IgA) Seroconversion: 6 & 10 Week vs. 6, 10, & 14 Week Vaccination Schedules — 28.9; 43.4 percentage of participants — p=0.014
N/A N=124 Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA
Premature Infants
Primary: Number of Injections Per Patient Per Season — 3.8; 3.9; 4.0; 1.0 Injections administered
N/A N=300 Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1).
Type 1 Diabetes Mellitus
Primary: Adherence to Regional Guidelines for the Immunization of Adults With Type 1 Diabetes Mellitus (T1DM — 165; 54; 51; 30 Participants
Phase 3 N=2,167 Safety and Immune Response of Different Pediatric Combination Vaccines.
Diphtheria · Polio · Pertussis
Primary: Percentage of Participant Responding to Pertussis Antigens Post-Dose 3 of Pentacel® or DAPTACEL®, IPOL®, and ActHIB® Vaccinations. — 98; 99; 99; 99 Percentage of…
Phase 4 N=72 Alternate Dosing Schedules Study for HPV Vaccine
Cervical Cancer · Genital Warts
Primary: Pain Following HPV Vaccine — 17; 32 participants
Phase 4 N=66 An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)
Diarrhea · Gastroenteritis
Primary: G1 Serum-neutralizing Antibody — 188; 184.5 titers
N/A N=608 Enhancing Health Care Access With Cellular Technology
Vaccination
Primary: Immunization Rate — 41.7; 40.1; 50.0 Percentage of immunizations
Phase 3 N=1,631 Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules
Meningococcal Disease
Primary: Percentages of Subjects With hSBA Titer ≥1:4 After Receiving One, Two or Three Doses of rMenB+OMV NZ Vaccine. — 42; 47; 41; 38 percentage of Subjects
Phase 4 N=156 Vaccinating Children After Chemotherapy
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Protective Titres to PCV13 Serotypes Post-immunization With PCV13+PPV23 — 40; 22 Participants
Phase 2 N=1,885 Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules
Meningococcal Infections
Primary: Percentage of Subjects With Serum Bactericidal Activity ≥1:5 After Receiving Three Doses of rMenB+OMV NZ Vaccine — 9; 7; 6; 6 Percentages of subjects
N/A N=7,404 Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
Immunization Status · Well Child Care Visit
Primary: Fully Vaccinated (Tdap, Menactra and 3 Doses of HPV (if Female)) — 143; 160; 100 participants — p=<0.05
N/A N=7,546 Primary Care and Adolescent Immunization for Rochester
Adolescent Immunizations · Preventive Care
Primary: Receipt of Adolescent Immunization at End of Study Period (Tdap, Menactra, HPV) — 1091; 885; 1783; 1367 participants
Phase 2 N=479 Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants
Malaria
Primary: Number of Subjects Reported With Serious Adverse Events (SAEs) — 5; 4; 5; 7 Participants
Phase 3 N=825 Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)
Rabies
Primary: Rabies Virus Neutralizing Antibody Concentrations on Day 14. — 3.1; 3.3 IU/mL
Phase 3 N=1,315 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
Bacterial Infections · Virus Diseases
Primary: Acceptability of Antibody (Ab) Response or Seroresponse Rates to All Antigens Contained in PR5I Vaccine One Month After the Toddler Dose of PR5I (11 to 12 Months of Age)…
N/A N=60 VISTA: Vaccinator-Initiated Screening and TAilored Counseling for Reducing Vaccine Hesitancy
Vaccination Uptake
Primary: Percentage of Women With Reduced Number of Concerns Immediately Post-counseling in the Intervention Arm — 51.72 percentage of women
Phase 3 N=1,250 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
Bacterial Infections · Virus Diseases
Primary: Percentage of Participants Vaccinated With PR5I With Acceptable Antibody (Ab) Response to Haemophilus Influenzae Type b, Diphtheria, Tetanus, and Poliovirus Types 1, 2 &…
Phase 4 N=1,271 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)
Hepatitis A Virus
Primary: Seropositivity Rate (SPR) to Hepatitis A — 100; 100; 100; 100 Percentage of participants
Phase 4 N=221 Fever After Simultaneous Versus Sequential Vaccination in Young Children
Fever After Vaccination · Fever · Febrile Seizure
Primary: Number of Participants With Fever Following Vaccination — 8; 10 Participants — p=0.7588
N/A N=228,831 Precision Vaccine Promotion in Underserved Populations
Influenza · Vaccine Hesitancy
Primary: Number of Participants Vaccinated at the End of the Campaign Period — 33357; 854 Participants — p=0.216
Phase 4 N=306 Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination
Hepatitis B
Primary: Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations as Measured by ELISA Equal to or Above Cut-off Value — 266 Participants
N/A N=660 Vaccine Health Literacy Related Text Message Reminders to Increase Receipt of Second Dose of Influenza Vaccine for Young, Low Income, Urban Children
Influenza
Primary: Receipt of 2nd Dose of the Influenza Vaccine. — 72.7; 66.7; 57.1 percentage of participants